Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Indianapolis, Indiana 46202


The purpose of this study to explore the combination of Revlimid®, oral cyclophosphamide and prednisone (RCP) in patients with newly diagnosed multiple myeloma.

Study summary:

This is a phase II single institution trial in patients with newly diagnosed multiple myeloma. Revlimid® 25 mg p.o. daily on days 1-21 of each 28-day cycle. Cyclophosphamide 50 mg p.o. BID daily on days 1-21 of each 28-day cycle. Prednisone 50 mg p.o. Q.O.D..


Inclusion Criteria: Patients with newly diagnosed, symptomatic multiple myeloma based on the following criteria: - Presence of an M-component in serum and/or urine plus clonal plasma cells in the bone marrow and/or a documented clonal plasmacytoma PLUS one or more of the following: - Calcium elevation (11.5 mg/dl) [42.65 mmol/l] - Renal insufficiency (1.5 x the ULN of serum creatinine) - Anemia (hemoglobin <=10 g/dl or 2 g/dl <= normal) - Bone disease (lytic lesions or osteopenia) Measurable disease is defined at least one of the following three measurements: - Serum M-protein >=1 g/dl ( or 10 g/l) - Urine M-protein >=200 mg/24 h - Serum FLC assay: Involved FLC level >=10 mg/dl (>=100 mg/l) provided serum FLC ratio is abnormal - Measurable plasmacytoma - NOTE: If a patient meets the criteria for symptomatic multiple myeloma but does not meet serum M-protein, urine M-protein or serum FLC levels stated above, percent plasma cells in bone marrow will be used to follow response. Laboratory test results within these ranges: - Absolute neutrophil count >= 1.0 x 109/L - Platelet count >= 50 x 10(9)/L - Hemoglobin >= 9 gm/dl - Serum creatinine <= 2.5mg/dL. - Total bilirubin <=1.5 x upper limit of normal - AST (SGOT) and ALT (SGPT) <= 3 x ULN Exclusion Criteria: - Known hypersensitivity to thalidomide - The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs. - Patients with a solitary plasmacytoma - Patients with uncontrolled diabetes - Patients with ≥ Grade 3 sensory neuropathy - History of cardiac disease, with NYHA Class II or greater



Primary Contact:

Principal Investigator
Attaya Suvannasankha, M.D.
Indiana University School of Medicine

Backup Contact:


Location Contact:

Indianapolis, Indiana 46202
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: June 25, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.